Phoenix Rising tells QMUL: release the PACE trial data
Mark Berry, Acting CEO of Phoenix Rising, presents the Board of Directors’ open letter to Queen Mary University of London (QMUL) urging them to release the PACE trial data, and hopes that other non-UK organisations will join British charities in the same request...
Discuss the article on the Forums.

Postinfectious and CF Syndromes: Clinical Experience from Norway

Discussion in 'Latest ME/CFS Research' started by leelaplay, Apr 13, 2010.

  1. leelaplay

    leelaplay member

    Tom Kindlon posted this to CO-CURE today

    show details 8:07 PM (17 hours ago)

    [B]Postinfectious and Chronic Fatigue Syndromes: Clinical Experience from a Tertiary-referral Centre in Norway[/B]

    H Naess, E Sundal, KM Myhr, and HI Nyland

    In Vivo, March 1, 2010; 24(2): 185-8.

    Department of Neurology, Haukeland University Hospital, University of
    Bergen, N-5021 Bergen, Norway.

    BACKGROUND: We aimed to compare patients reporting acute infection with
    those reporting no infection at onset of chronic fatigue syndrome (CFS).

    PATIENTS AND METHODS: This study includes 873 patients with CFS referred to
    a tertiary centre on average 4.8 years after symptom onset. Assessment was
    by both observer query and self-reports. Antibody analyses against
    infectious agents including Epstein-Barr virus and enterovirus were
    performed in a majority of patients.

    RESULTS: Females comprised 75.3% of the patient group, and the mean age was
    33 years. Initial infection was reported by 77%. There was no difference as
    to antibody analyses. Logistic regression showed that initial infection was
    independently associated with acute onset of fatigue, improvement of fatigue
    at referral, and the following symptoms at referral: fever, tender lymph
    nodes, and myalgia.

    CONCLUSION: CFS patients with initial infection as a precipitating factor
    more often report acute onset of fatigue, more frequent accompanying
    symptoms, and more frequent improvement on referral than do patients without
    initial infection.

    PMID: 20363992


See more popular forum discussions.

Share This Page